Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | PKLR | P30613 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8095011 | 0.88 | GAA (0.51) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL1677156 | 0.83 | HTT (0.65) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL8211817 | 0.82 | HTT (0.64) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL27370216 | 0.82 | HTT (0.70) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL4380828 | 0.81 | SMN1; SMN2 (0.53) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL2297519 | 0.81 | HTT (0.53) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL14625303 | 0.80 | HTT (0.68) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL29944227 | 0.80 | HTT (0.68) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL4385367 | 0.79 | HTT (0.51) | GAAHTTPKMPKLRLMNA | |
| SCHEMBL4379438 | 0.79 | HTT (0.51) | GAAHTTPKMPKLRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2011-08-04 | — | — | US | disclosed |
| EP-2164326-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | Euro-Celtique, S.A. (LU) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150447-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190300-A1 | AMIDE COMPOUNDS AND THE USE THEREOF | CACNA1E, CACNA1B, CACNA1S | GAA 3413/4885HTT 2426/4885PKM 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.